SCHEMBL31234818

SCHEMBL31234818

CCC(C)(C)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
ALOX15 P16050 1/20 0.55
NFKB1 P19838 1/20 0.55
PTGS2 P35354 1/20 0.55
THPO P40225 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ACE P12821 4/20 0.50
RIPK1 Q13546 2/20 0.44
FOLH1 Q04609 1/20 0.43
GRN P28799 1/20 0.38
SORT1 Q99523 1/20 0.38
MME P08473 2/20 0.38
ACE2 Q9BYF1 1/20 0.38
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL929062 0.87 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL7718893 0.87 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL929540 0.87 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL6661779 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL6661780 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL9324856 0.82 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27397337 0.82 KDM4E (0.52) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL928213 0.81 KDM4E (0.55) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL12426218 0.81 RIPK1 (0.44) MAPTRIPK1GRNSORT1MME
SCHEMBL11940951 0.81 RIPK1 (0.44) MAPTRIPK1GRNSORT1MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688734-A1 CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA Lento Bio, Inc. (US) 2026-02-11 EP disclosed
US-20260035345-A1 N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA LENTO BIO, INC. (US) 2026-02-05 US disclosed
WO-2024243373-A1 CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA LENTO BIO, INC. (US) 2024-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035345-A1 N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA CRYAB, CRYAA, CRYZ KDM4E 1882/4885MAPT 2090/4885THRB 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.